These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28097342)

  • 1. Second Chances to Improve ESRD Outcomes With a Second-Generation Calcimimetic.
    Middleton JP; Wolf M
    JAMA; 2017 Jan; 317(2):139-141. PubMed ID: 28097342
    [No Abstract]   [Full Text] [Related]  

  • 2. [Mechanism of uremic osteodystrophy and prevention of hyperparathyroidism in the uremic patient].
    Brancaccio D; Cozzolino M; Galassi A; Bellasi A; Carpani P; Gallieni M
    G Ital Nefrol; 2003; 20 Suppl 22():S12-6. PubMed ID: 12851915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
    Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
    Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease.
    Quarles LD; Sherrard DJ; Adler S; Rosansky SJ; McCary LC; Liu W; Turner SA; Bushinsky DA
    J Am Soc Nephrol; 2003 Mar; 14(3):575-83. PubMed ID: 12595492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bimaxillary full arch fixed dental implant supported treatment for a patient with renal failure and secondary hyperparathyroidism and osteodystrophy.
    Flanagan D; Mancini M
    J Oral Implantol; 2015 Apr; 41(2):e36-43. PubMed ID: 24372491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Use of Calcimimetics for the Treatment of Secondary Hyperparathyroidism: A 10 Year Evidence Review.
    Rodríguez M; Goodman WG; Liakopoulos V; Messa P; Wiecek A; Cunningham J
    Semin Dial; 2015; 28(5):497-507. PubMed ID: 25752650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Calcimimetic drugs in stage 3-5 chronic kidney disease].
    Grzegorzewska AE; Niepolski L
    Pol Merkur Lekarski; 2012 Apr; 32(190):260-2. PubMed ID: 22708286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Parenteral calcimimetics for the treatment of secondary hyperparathyroidism.].
    Hamano N; Fukagawa M
    Clin Calcium; 2017; 27(4):567-572. PubMed ID: 28336834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future role of calcimimetics in end-stage renal disease.
    Goodman WG; Turner SA
    Adv Ren Replace Ther; 2002 Jul; 9(3):200-8. PubMed ID: 12203202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism.
    Cunningham J; Danese M; Olson K; Klassen P; Chertow GM
    Kidney Int; 2005 Oct; 68(4):1793-800. PubMed ID: 16164656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the potential value of improved care for secondary hyperparathyroidism with a novel calcimimetic therapy.
    Stollenwerk B; Iannazzo S; Cooper K; Belozeroff V
    J Med Econ; 2017 Oct; 20(10):1110-1115. PubMed ID: 28803497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dysphoria induced in dialysis providers by secondary hyperparathyroidism.
    Soomro IH; Goldfarb DS
    Clin J Am Soc Nephrol; 2015 Jan; 10(1):9-11. PubMed ID: 25516914
    [No Abstract]   [Full Text] [Related]  

  • 13. Calcimimetic agents: review and perspectives.
    Ureña P; Frazão JM
    Kidney Int Suppl; 2003 Jun; (85):S91-6. PubMed ID: 12753275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current therapeutic options for the treatment of secondary hyperparathyroidism in end-stage renal disease patients treated with hemodialysis: a 12-month comparative study.
    Dudar I; Shifris I; Dudar S; Kulish V
    Pol Merkur Lekarski; 2022 Oct; 50(299):294-298. PubMed ID: 36283011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.
    Henley C; Yang Y; Davis J; Lu JY; Morony S; Fan W; Florio M; Sun B; Shatzen E; Pretorius JK; Richards WG; St Jean DJ; Fotsch C; Reagan JD
    J Pharmacol Exp Ther; 2011 Jun; 337(3):681-91. PubMed ID: 21422163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changing landscape of the treatment of hyperparathyroidism related to end-stage renal disease-can we turn the clock backward?
    Kruijff S; van der Plas WY; Dulfer RR; Vriens MR; van Ginhoven TM; Engelsman AF; Delbridge LW
    Surgery; 2019 Feb; 165(2):289-290. PubMed ID: 30266441
    [No Abstract]   [Full Text] [Related]  

  • 18. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
    Strippoli GF; Tong A; Palmer SC; Elder G; Craig JC
    Cochrane Database Syst Rev; 2006 Oct; (4):CD006254. PubMed ID: 17054287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration.
    Díaz-Tocados JM; Rodríguez-Ortiz ME; Almadén Y; Pineda C; Martínez-Moreno JM; Herencia C; Vergara N; Pendón-Ruiz de Mier MV; Santamaría R; Rodelo-Haad C; Casado-Díaz A; Lorenzo V; Carvalho C; Frazão JM; Felsenfeld AJ; Richards WG; Aguilera-Tejero E; Rodríguez M; López I; Muñoz-Castañeda JR
    Kidney Int; 2019 May; 95(5):1064-1078. PubMed ID: 30878213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cinacalcet improves control of secondary hyperparathyroidism in peritoneal dialysis: a multicenter study.
    Portolés J; López-Sánchez P; Bajo MA; Castellano I; del Peso G; Rodríguez JR; Ribera M; Ortigosa A; Selgas R
    Perit Dial Int; 2012; 32(2):208-11. PubMed ID: 22383721
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.